コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 the tumor microenvironment, as normalization cancer immunotherapy.
2 tic agents with unique effector functions in cancer immunotherapy.
3 ong the survival of T cells for personalized cancer immunotherapy.
4 new mechanisms and biomarkers for anti-dMMR-cancer immunotherapy.
5 ssing T cells are the main effector cells in cancer immunotherapy.
6 ous cancers makes it an important target for cancer immunotherapy.
7 may be required to enable the most effective cancer immunotherapy.
8 s is important for the success of cell-based cancer immunotherapy.
9 tions and future promise within the field of cancer immunotherapy.
10 the identification of relevant antigens for cancer immunotherapy.
11 odified immune cells holds great promise for cancer immunotherapy.
12 g the feasibility of CRISPR gene editing for cancer immunotherapy.
13 ts an attractive new therapeutic approach in cancer immunotherapy.
14 gression, and response to therapy, including cancer immunotherapy.
15 s should be explored to improve responses to cancer immunotherapy.
16 (6)A demethylase Alkbh5 sensitized tumors to cancer immunotherapy.
17 i-tumor immunity, which has implications for cancer immunotherapy.
18 diabetes treatment, and T cell delivery for cancer immunotherapy.
19 l exclusion and improve clinical benefits of cancer immunotherapy.
20 icted expression pattern to target them with cancer immunotherapy.
21 fective strategy to increase the efficacy of cancer immunotherapy.
22 A INCR1 and suggest a therapeutic target for cancer immunotherapy.
23 ve the treatment outcome of adenovirus-based cancer immunotherapy.
24 rroptosis is involved in T cell immunity and cancer immunotherapy.
25 e and as a scaffold, sets it as a target for cancer immunotherapy.
26 r the future that could widen the success of cancer immunotherapy.
27 identification of potential new targets for cancer immunotherapy.
28 nts or autoimmune disease who are undergoing cancer immunotherapy.
29 accine offers a robust and safe strategy for cancer immunotherapy.
30 ll death receptor-1 (PD1), a major target in cancer immunotherapy.
31 such, it has been successfully exploited for cancer immunotherapy.
32 nism and have implications for the design of cancer immunotherapy.
33 n tumor immune evasion and poor responses to cancer immunotherapy.
34 hat can induce and enhance ICD to potentiate cancer immunotherapy.
35 pid metabolism in M2-like TAMs could improve cancer immunotherapy.
36 th infection prevention and repurposing as a cancer immunotherapy.
37 c-15 as a potential target for normalization cancer immunotherapy.
38 ng their potential as an important target in cancer immunotherapy.
39 toring systems and predictive biomarkers for cancer immunotherapy.
40 lerance but are a major barrier to effective cancer immunotherapy.
41 d might, therefore, be potential targets for cancer immunotherapy.
42 breast cancer, and is a promising target for cancer immunotherapy.
43 or growth, represent an attractive target in cancer immunotherapy.
44 e therapeutic potential for CD24 blockade in cancer immunotherapy.
45 iding a novel mechanism for potential use in cancer immunotherapy.
46 oline TLR7/8 agonists for vaccine design and cancer immunotherapy.
47 preciation that NK cells can be harnessed in cancer immunotherapy.
48 evelopment of enhanced T cell strategies for cancer immunotherapy.
49 and provide a potential strategy to improve cancer immunotherapy.
50 locker drugs) could be repurposed for use in cancer immunotherapy.
51 esign, and neoantigen binding prediction for cancer immunotherapy.
52 critical for designing RORgamma agonists for cancer immunotherapy.
53 osuppressive myelopoiesis in tumors to boost cancer immunotherapy.
54 als that may position them as key players in cancer immunotherapy.
55 and enhance the efficacy of various forms of cancer immunotherapy.
56 acles to using personalized neoantigen-based cancer immunotherapy.
57 NR4A inhibition as a promising strategy for cancer immunotherapy.
58 exhaustion are major barriers to successful cancer immunotherapy.
59 nterest in modulating DC function to improve cancer immunotherapy.
60 pes simplex virus 1 is a promising agent for cancer immunotherapy.
61 rness currently available WNT modulators for cancer immunotherapy.
62 y that is emerging as a viable candidate for cancer immunotherapy.
63 infections such as malaria HIV/AIDS, and for cancer immunotherapy.
64 allogeneic NK cells holds great promise for cancer immunotherapy.
65 biomarker to identify patients responding to cancer immunotherapy.
66 ay provide a unique therapeutic approach for cancer immunotherapy.
67 n situ, which has great potential for use in cancer immunotherapy.
68 th a vaccine for infectious disease and as a cancer immunotherapy.
69 T cell dual-costimulation in the context of cancer immunotherapy.
70 coupling of a telomerase peptide relevant to cancer immunotherapy.
71 ial for pharmacological targeting to enhance cancer immunotherapy.
72 ors and have emerged as a major obstacle for cancer immunotherapy.
73 t caveolin-2 could be a potential target for cancer immunotherapy.
74 validation of affected genes and targets for cancer immunotherapy.
75 iderable hurdles to immune cell function and cancer immunotherapy.
76 optogenetics to overcome critical hurdles in cancer immunotherapy.
77 bsets with properties critical for improving cancer immunotherapy.
78 acter of NK cells most desired for effective cancer immunotherapy.
79 iveness of conventional therapies as well as cancer immunotherapy.
80 tory functions and are of clear interest for cancer immunotherapy.
81 ing, which can be exploited for personalized cancer immunotherapy.
82 c antigen receptor (CAR)-modified T cells in cancer immunotherapy.
83 ctive biomarker for efficacious responses to cancer immunotherapy.
84 ble off-target toxicity of TNFSF ligands for cancer immunotherapy.
85 re suitable platforms as novel adjuvants for cancer immunotherapy.
86 using gene mutations or engineer T cells for cancer immunotherapy.
87 of antitumor immune responses and success of cancer immunotherapy.
88 that could provide opportunities to improve cancer immunotherapy.
89 n activating the body's immune responses for cancer immunotherapy.
90 noengineering approaches towards activatable cancer immunotherapy.
91 le Alkbh5 inhibitor enhanced the efficacy of cancer immunotherapy.
92 es the efficacy of dendritic cell (DC)-based cancer immunotherapy.
93 lymphatic vessels in tumor dissemination and cancer immunotherapy.
94 ker (granzyme B) for real-time evaluation of cancer immunotherapy.
95 e is one of the most promising strategies of cancer immunotherapy.
96 tratumoral T(reg) cells is direly needed for cancer immunotherapy.
97 uch, blockade of GPR81 signaling could boost cancer immunotherapy.
98 dysfunction, with important implications for cancer immunotherapy.
99 s should provide novel strategies to enhance cancer immunotherapy.
100 mulate into tumors, hindering the success of cancer immunotherapy.
101 cells, rendering them attractive targets for cancer immunotherapy.
102 ery of previously unknown tumor antigens for cancer immunotherapy.
103 rventions that exploit metabolism to improve cancer immunotherapy.
104 ome one of the most investigated targets for cancer immunotherapy.
105 as well as how to exploit their behavior for cancer immunotherapy.
106 which eventually contribute to personalized cancer immunotherapy.
107 s to create superior clinical candidates for cancer immunotherapy.
108 dered a major limitation for the efficacy of cancer immunotherapy.
109 nce to identify patients responding early to cancer immunotherapy.
110 oral CD8(+) T cells in patients treated with cancer immunotherapy.
111 s the progress and problems of NK cell-based cancer immunotherapies.
112 h as monitoring the efficacy of vaccines and cancer immunotherapies.
113 clinically for the generation of cell-based cancer immunotherapies.
114 t is a requirement to develop more effective cancer immunotherapies.
115 tine supplementation to improve T cell-based cancer immunotherapies.
116 oint blockade and adoptive T cell therapy as cancer immunotherapies.
117 ould be valuable for vaccine development and cancer immunotherapies.
118 and cancer cells to optimize the efficacy of cancer immunotherapies.
119 to realize their translation into effective cancer immunotherapies.
120 uppressive and negatively impact response to cancer immunotherapies.
121 s imperative to the development of effective cancer immunotherapies.
122 t toward advertising high-cost biologics and cancer immunotherapies.
123 e risk, infectious disease pathogenesis, and cancer immunotherapies.
124 nd highlight obesity as a biomarker for some cancer immunotherapies.
125 ells and can thereby improve the efficacy of cancer immunotherapies.
126 g could lead to new, improved generations of cancer immunotherapies.
127 e poised to become a main pillar of cellular cancer immunotherapies.
128 is critical for the development of effective cancer immunotherapies.
129 an important resistance mechanism to current cancer immunotherapies.
130 used to develop multiantigenic, personalized cancer immunotherapies.
131 xhaustion is a major barrier to current anti-cancer immunotherapies.
132 ans leading to the development of innovative cancer immunotherapies.
133 vestigates the physical processes that drive cancer immunotherapies.
134 nt cancer types and following treatment with cancer immunotherapies.
135 y bacteria(10-12) and synthetic CDNs used in cancer immunotherapy(13,14), must traverse the cell memb
136 lymphocyte-associated protein 4 (CTLA-4) for cancer immunotherapy, a large number of patients and can
142 From their associations with resistance to cancer immunotherapies and microbial infections, we unco
143 ms as well as the use of these approaches in cancer immunotherapies and their potential adverse effec
145 tory T cells (Tregs) have been implicated in cancer immunotherapy and are also an emerging cellular t
146 y CTLA4 activity is blocked by antibodies in cancer immunotherapy and augmented by the provision of s
147 maging of immunoactivation is imperative for cancer immunotherapy and drug discovery; however, most e
148 7 may be targeted to enhance T-cell-mediated cancer immunotherapy and improve T effector cell accumul
152 a in facilitating autoimmune toxicity during cancer immunotherapy and presents a safe and powerful co
153 application of ex vivo expanded NK cells in cancer immunotherapy and provide a translational humaniz
154 Our study has important implications for cancer immunotherapy and suggest that exhausted NK cells
155 genic peptides and is an emerging target for cancer immunotherapy and the control of autoimmunity.
156 cade, the trafficking of immune cells during cancer immunotherapy and the distribution of cells after
157 eral systemic immune response as enhancement cancer immunotherapy and those that target a specific dy
159 didates for use in vaccination and TCR-based cancer immunotherapies, and datasets generated by this t
161 sed for characterizing the TME for precision cancer immunotherapy, and discuss important consideratio
163 Molina Foundation, the Parker Institute for Cancer Immunotherapy, and the National Institute of Neur
164 s for integrating delivery technologies into cancer immunotherapy, and we critically analyse the outl
167 of TLR9 signaling, which may be critical in cancer immunotherapy approaches and coordinating the inn
171 rticle, the background and current status of cancer immunotherapy are summarized, and the current met
172 Our study has important implications for cancer immunotherapy as we define key transcription fact
174 cine was awarded to pioneers in the field of cancer immunotherapy, as the utility of leveraging a pat
175 mples in vaccines for infectious disease and cancer immunotherapy, as well as settings of immune regu
176 tracellular vesicles (EV) are candidates for cancer immunotherapy because of their capacity to stimul
177 results of select recent clinical studies of cancer immunotherapies beyond anti-CTLA-4 and anti-PD(L)
179 kpoint inhibitors (ICIs) have revolutionised cancer immunotherapy but their success is wholly depende
180 cells are central to all currently effective cancer immunotherapies, but the characteristics defining
181 1) inhibitors are speculated to be useful in cancer immunotherapy, but a phase III clinical trial of
182 approaches have revolutionized the field of cancer immunotherapy, but hurdles remain, especially for
183 ve cell therapy represents a new paradigm in cancer immunotherapy, but it can be limited by the poor
184 pes of cationic lipids have shown promise in cancer immunotherapy, but their mechanism of action is p
185 h a novel technology that enhances oncolytic cancer immunotherapy by capitalizing on pre-acquired imm
187 lights a strategy to enhance the efficacy of cancer immunotherapy by scavenging extracellular ROS usi
188 results of the IDO1 inhibitor epacadostat in cancer immunotherapy call for a better understanding of
191 hocytes (CTL) are the preferred effectors of cancer immunotherapy, CD4(+) T-cell help is also require
192 vironment and assess their associations with cancer immunotherapy, chemotherapy, and radiation therap
197 terest, given their potential importance for cancer immunotherapy, disease outcomes, vaccination and
198 ges, but there is a heated debate on whether cancer immunotherapy efficacy is different between male
199 er types have limitations to discern whether cancer immunotherapy efficacy is different between male
201 onally designed nanostructures to circumvent cancer immunotherapy failures, (2) bioengineered tumor m
202 lieve the integration of nanotechnology with cancer immunotherapy for nano-immunotherapeutics provide
203 n address some of the emerging challenges in cancer immunotherapy, for example (i) enabling combinati
204 y, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established
205 highlight key parameters that differentiate cancer immunotherapy from conventional cytotoxic agents,
211 T) of engineered T cell receptors (TCRs) for cancer immunotherapy has evolved from simple gene transf
213 of negative checkpoint regulators (NCRs) for cancer immunotherapy has garnered significant interest w
214 Repurposing drugs from autoimmunity and cancer immunotherapy has rapidly yielded important advan
216 epurposing these drugs from autoimmunity and cancer immunotherapy has yielded important advancements
225 ligand 1 (PD-L1) is a key factor influencing cancer immunotherapy; however, the regulation of PD-L1 e
227 dings suggest a new combination strategy for cancer immunotherapy in patients with EpCAM-expressing t
228 ntibodies to the receptor have been used for cancer immunotherapy in preclinical models and are curre
230 arnered significant attention in the area of cancer immunotherapy, in which efforts have focused in p
233 es, several outstanding questions remain for cancer immunotherapy, including how to make immunotherap
242 eneration, therapeutic protein delivery, and cancer immunotherapy is reviewed, with a focus on progre
252 the immune response and development of novel cancer immunotherapy not limited by HLA allele prevalenc
254 has led to investigations into the impact on cancer immunotherapies, particularly with agents targeti
255 ing transformed and malignant cells, and how cancer immunotherapies potentiate NK cell responses for
257 adjuvants to safely enhance the efficacy of cancer immunotherapy, radiotherapy, or 'immunogenic' che
259 re has been shown to improve the efficacy of cancer immunotherapies, recent studies suggest that enha
260 hich are directly cytotoxic to tumour cells, cancer immunotherapy relies on the host's immune system
266 d in drug development and clinical trials of cancer immunotherapy.See related article by Xiao et al.,
267 CRISPR screens in CD8 T cells directly under cancer immunotherapy settings and identified regulators
271 , the strategies to engineer macrophages for cancer immunotherapy, such as inhibition of macrophage r
272 ntraindications for the perioperative use of cancer immunotherapy, suggest safe immunotherapeutic and
273 success with immune checkpoint inhibitors in cancer immunotherapy suggests a dysfunctional immune syn
276 ing steps in the development of personalized cancer immunotherapies that are based on vaccination or
277 t bispecific antibodies (TDBs) are promising cancer immunotherapies that recruit a patient's T cells
280 nces in clinical implementation of p53-based cancer immunotherapy, they highlight the importance of p
281 focus on how intestinal microbiota influence cancer immunotherapy through activating gut immunity.
282 oimmune diseases such as lupus as well as in cancer immunotherapy through CAR-T cell or checkpoint bl
283 rationale for enhancing PD-1/PD-L1-targeted cancer immunotherapy through co-targeting mTORC1/p70S6K
284 on, thereby paving new ways for potentiating cancer immunotherapy through epigenetic reprogramming of
285 he interest in integrating nanomedicine with cancer immunotherapy to further improve clinical respons
286 currence rates, is of integral importance in cancer immunotherapy to inform management and treatment
287 This has led to the development of targeted cancer immunotherapy, to enhance immune surveillance aga
289 identifying potential biomarkers of irAE in cancer immunotherapy using both pharmacovigilance data a
291 r, enabling a novel personalized approach to cancer immunotherapy using off-the-shelf therapeutics.
292 he foundation for the recent exciting era of cancer immunotherapy, which includes immune checkpoint b
293 Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidenc
294 rditis for application in clinical trials of cancer immunotherapies will enable greater understanding
298 Monitoring the pharmacodynamic activity of cancer immunotherapy with novel molecular imaging tools
299 that combine natural killer (NK) cell-based cancer immunotherapy with radiotherapy and chemotherapy